



ASX : IPD

30th July 2008

ASX ANNOUNCEMENT - APPENDIX 4C – CASH FLOW QTR ENDED 30 JUNE 2008

ImpediMed Limited today releases its Appendix 4C quarterly cash flow report for the period ended 30th June 2008.

The results in the cash flow report are consistent with expectations behind the company's use of funds projections in its 2007 prospectus.

Highlights of the quarter included :

- Quarter sales revenue of \$873K taking sales revenue for the financial year 2008 to \$2.3 Million (unaudited). March quarter sales for year 2008 were \$579K and comparable sales for the June Quarter of the previous financial year 2007 were \$311K.
- The Publication in the online edition of the journal Cancer of a pivotal study by the NIH and the National Naval Medical Center in the US, which found that the preoperative assessment of breast cancer patients for subclinical lymphoedema enables clinicians to establish a baseline, which serves to enable the early diagnosis and successful treatment of this debilitating condition.
- Acknowledgment of bioimpedance spectroscopy in the Northern Ireland Guidelines for the Assessment and Monitoring of Lymphoedema as the only technology high in sensitivity and specificity.
- The April 2008 Lymphology Journal publication of a longitudinal study, by Dr Sandra Hayes of QUT, of almost 300 Australian women diagnosed with breast cancer, which found ImpediMed's technology, bioimpedance spectroscopy (BIS), to be the most direct accurate and reliable method for assessment and diagnosis of secondary Lymphoedema.
- A very strong response from Breast Surgeons at the ASBS Conference in New York in May in terms of sales leads generated.
- The July 2008 Journal of Clinical Oncology publication which demonstrated that Lymphoedema is a common disease in breast cancer patients and that the use of BIS technology would become increasingly more important, especially as treatment shifts to early detection and early intervention.
- The official opening of ImpediMed's San Diego based US facility by Queensland Premier, the honourable Anna Bligh, signifying the company's establishment of a logistical hub to support its expansion into the US market.

The negative cash flow from operations for the quarter was (\$2,271K) down from (\$2,354K) in the March 2008 quarter.

Cash on hand at 30th June 2008 was \$8.485M. In the month following the 30 June balance date the company has raised a further \$4.2M to support an acceleration of the company's expansion in the US Market.

Greg Brown
CEO

Phil Auckland
CFO & COO

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity

ImpediMed Limited

ABN

65 089 705 144

Quarter ended ("current quarter")

30th June 2008

Consolidated statement of cash flows

Cash flows related to operating activities	4th Quarter 2008 \$A'000	Year to date (12 months) \$A'000
1.1 Receipts from customers	376	1,711
1.2 Receipts from grants	585	1,252
1.3 Payments to suppliers and employees	(3,400)	(11,575)
1.4 Interest received	191	602
1.5 Interest paid	9	(7)
1.6 R&D tax offset received	0	0
1.7 Other (provide details if material)	(32)	0
Net operating cash flows	(2,271)	(8,016)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	4th Quarter 2008 \$A'000	Year to date (12 months) \$A'000
1.8	(2,271)	(8,016)
1.9	Cash flows related to investing activities	
	Payment for acquisition of:	
	(a) businesses (item 5)	(1,352)
	(b) equity investments	0
	(c) intellectual property	0
	(d) physical non-current assets	(274)
	(e) other non-current assets	(1,344)
1.10	Proceeds from disposal of:	
	(a) businesses (item 5)	0
	(b) equity investments	0
	(c) intellectual property	0
	(d) physical non-current assets	0
	(e) other non-current assets	71
1.11	Loans to other entities	0
1.12	Loans repaid by other entities	0
1.13	Other (provide details if material)	74
	Net investing cash flows	(2,826)
1.14	Total operating and investing cash flows	(10,842)
1.15	Cash flows related to financing activities	
	Proceeds from issues of shares, options, etc.	
	Gross proceeds from IPO – Public Offer	9,792
	Gross proceeds from IPO – Redemption	8,208
	Issue	7,894
	Gross proceeds from Conversion of Pref Sh	14,339
	Gross proceeds from Conv of S3 Conv Note	
	Gross proceeds from issue of shares to	1,156
	Xitron Shareholders	
1.16	Costs from capital raise	(991)
1.17	Proceeds from borrowings	8,208
1.18	Repayment of borrowings	
	Repayment of IPO Convertible Notes	(8,208)
	Repayment of Preference Shares	(7,894)
	Repayment of S3 Conv Note	(14,339)
	Repayment of Xitron bank loan	(563)
	Other repayments	(83)
1.19	Dividends paid	0
1.20	Other (provide details if material)	195
	Net financing cash flows	17,714

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Net financing cash flows (carry forward)	227	17,714
1.21	Net increase (decrease) in cash held	(1,726)	6,873
1.22	Cash at beginning of quarter/year to date	10,211	1,612
1.23	Exchange rate adjustments to items 1.12, 1.20	0	1
1.24	Cash at end of quarter	8,485	8,485

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related entities

		4th Quarter 2008 \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.3	161
1.25	Aggregate amount of loans to the parties included in item 1.11	N/A

1.26 Explanation necessary for an understanding of the transactions

Payments to directors consist of Directors' salaries and the Directors' fees for the quarter.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	—	—
3.2	Credit standby arrangements	—	—

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	4th Quarter 2008 \$A'000	3rd Quarter 2008 \$A'000
4.1 Cash on hand and at bank	1,554	1,516
4.2 Deposits at call	6,931	8,695
4.3 Bank overdraft	0	0
4.4 Other (provide details)	0	0
Total: cash at end of quarter (item 1.23)	8,485	10,211

Acquisitions and disposals of business entities

		Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	N/A	N/A
5.2	Place of incorporation or registration	N/A	N/A
5.3	Consideration for acquisition or disposal	N/A	N/A
5.4	Total net assets	N/A	N/A
5.5	Nature of business	N/A	N/A

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.



Sign here: Date:30th July 2008.....
(Director/Company secretary)

Print name: ...Phillip S. Auckland.....

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.
 - 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
 - 9.2 - itemised disclosure relating to acquisitions
 - 9.4 - itemised disclosure relating to disposals
 - 12.1(a) - policy for classification of cash items
 - 12.3 - disclosure of restrictions on use of cash
 - 13.1 - comparative information
3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.